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Background
To investigate the association between fasting serum insulin and glucose levels with atherosclerotic 
plaque composition in the carotid artery. Impaired insulin and glucose levels are implicated in the etiology 
of cardiovascular disease, however, their influence on the formation and composition of atherosclerotic 
plaque remains unclear.
Methods 
In 1740 participants (mean age 72.9 years, 46% women, 14.4 % diabetes mellitus) from the population-
based Rotterdam Study, we performed carotid MRI to evaluate the presence of calcification, lipid core, 
and intraplaque hemorrhage in carotid atherosclerosis. All participants also underwent blood sampling to 
obtain information on serum insulin and glucose levels. Using logistic regression models, we assessed 
the association of serum insulin and glucose levels (per standard deviation (SD) and in tertiles) with the 
different plaque components, while adjusting for sex, age, intima-media thickness, and cardiovascular risk 
factors. Results
Serum insulin levels were associated with the presence of intraplaque hemorrhage [adjusted odds ratio 
(OR): 1.42 (95% confidence interval (CI) 1.12–1.7)]. We found no association with the presence of 
calcification or lipid core. Sensitivity analyses restricted to individuals without diabetes mellitus yielded 
similar results. No associations were found between serum glucose levels and any of the plaque 
components.
Conclusions
Serum insulin levels are associated with the presence of vulnerable components of carotid plaque, 
specifically with intraplaque hemorrhage. These findings suggest a complex role for serum insulin in the 
pathophysiology of carotid atherosclerosis and in plaque vulnerability.
Key Words: carotid artery, insulin, glucose, intraplaque hemorrhage, lipid core, calcification, MRI, 
atherosclerosis, epidemiology.
INTRODUCTION
Dysregulations in insulin and glucose metabolism, the pathophysiological underpinnings of diabetes 
mellitus, are associated with an increased risk of cardiovascular disease due to the accelerated 
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accumulation of atherosclerosis (1, 2). Despite abundant evidence for the role of diabetes in the 
pathophysiology of atherosclerosis and clinical cardiovascular events, insights into the contribution of 
early disruptions in serum levels of insulin and glucose on the development of atherosclerosis remain 
scarce. Moreover, levels of serum insulin and their atherogenic properties are even conflicting (3-5). 
Another important topic of interest within the field of atherosclerosis, for which the role of serum levels of 
insulin and glucose are even more elusive, pertains to plaque composition. Plaque composition is directly 
related to the chances of a plaque to rupture and potentially result in clinical cardiovascular events (6-9). 
The vulnerability of a plaque to rupture is assessed by evaluation of the presence of vulnerable, non-
calcified plaque components such as lipid core or intraplaque hemorrhage (9), and the presence of 
calcification, which is regarded as a more plaque-stabilizing component (3-5). In-vivo visualization of the 
atherosclerotic plaque and its components can be non-invasively accomplished by magnetic resonance 
imaging (MRI) (10).
Against this background, we investigated the association between insulin and glucose levels with 
atherosclerotic plaque composition in the carotid artery in a large population-based cohort of subjects with 
subclinical atherosclerosis. 
METHODS
Study population
The Rotterdam Study is a prospective population-based cohort (11). Between 2007 and 2012 participants 
with carotid atherosclerosis were invited to undergo an MRI scan of the carotid arteries. Participants were 
selected for MRI based on the results of carotid artery ultrasound examination (intima-media thickness 
≥2.5 mm in one or both carotid arteries) performed in all participants of the Rotterdam Study. From the 
2666 invited participants, 272 refused to participate, and another 363 did not undergo an MRI scan due to 
claustrophobia (n=57), physical limitations (n=191), and MRI contraindication (n=115). From the 
remaining 1982 participants that underwent MRI scan, 242 were excluded due to bad image quality 
(n=95), the absence of plaque (n=41), or incomplete examinations due to claustrophobia during scanning 
(n=106). Hence, 1740 participants were included in the analyses (Figure 1). The Rotterdam Study 
complies with the Helsinki Declaration and has been approved by the Medical Ethics Committee of the 
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Erasmus MC and by the Dutch Ministry of Health, Welfare and Sports, implementing the “Wet Bevolkings 
Onderzoek: ERGO (Population Screening Act: Rotterdam Study)”. All participants provided written 
informed consent to participate in the study and to obtain information from their treating physicians.
Carotid scanning and analysis of plaque components
A magnetic resonance 1.5 Tesla scanner (GE Healthcare, Milwaukee, WI, USA) with a dedicated bilateral 
phased-array surface coil (Machnet, Eelde, the Netherlands) was used to perform bilateral multisequence 
imaging of the carotid arteries, with a standardized scanning protocol, that required an approximate total 
scanning time of 30 minutes. Details of the scanning protocol, reading procedure, and reproducibility are 
described in detail elsewhere (12, 13). Two independent readers, with three years of experience visually 
evaluated the carotid artery images for the presence of three plaque components, namely intraplaque 
hemorrhage (IPH), lipid core, and calcification. IPH was defined as the presence of a hyperintense region 
in the atherosclerotic plaque on 3D-T1w-GRE. Lipid core presence was defined as a hypointense region, 
not classified as IPH or calcification, in the plaque on PDw-FSE or PDw-EPI and T2w-EPI images or a 
region of relative signal intensity drop in the T2w-EPI images compared with the PDw-EPI images. 
Calcification was defined as the presence of a hypointense region in the plaque on all sequences (14). 
Subjects were recorded as positive for the presence of any plaque component if the component was 
identified in one or both carotid arteries. To assess the intra-scan variability, 40 participants underwent a 
second MRI scan (average time between scans 15 ± 9 days). For interobserver reproducibility analyses, 
random MRI examinations were selected (n = 50) and read by a second observer. Intra-scan and 
interobserver agreement were calculated by using Cohens’ Kappa statistics. The intra-scan agreement 
was good for all measurements. The Kappa value for the presence of IPH was 0.95 (95% CI 0.88–0.99); 
for lipid core 0.85 (95% CI 0.74–0.96) and for calcification 0.91 (95% CI 0.82–0.99). The interobserver 
agreement was good for all measurements. The Kappa value for IPH was 0.86 (95% CI 0.72–0.99); for 
lipid core 0.86 (95% CI 0.72–0.99) and for calcification 0.94 (95% CI 0.86–0.99) (13).
Assessment of fasting insulin and glucose levels
The venous blood samples were taken, after overnight fasting from all participants at the research center 
and stored at −80°C in a number of 5-mL aliquots. Serum fasting glucose levels were determined by 
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using the glucose hexokinase method within 1 week after sampling (15). Serum fasting insulin level was 
determined in samples that had been kept frozen and were measured on a Roche Modular Analytics 
E170 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) by electrochemiluminescence 
immunoassay technology. This assay does not cross-react with proinsulin or C-peptide. The intraassay 
repeatability showed a coefficient of variation of 1.0%. The day-to-day variation of the assay (i.e., 
intermediate precision) yielded a coefficient of variation of 3.6%. These numbers indicate the excellent 
reliability of the insulin assay in our study (16). We used the following formula to calculate the HOMA–IR 
index [fasting insulin (mU/L) × fasting glucose (mmol/L)] / 22.5 (17). The blood measurements were made 
for all participants at study entry and the mean time interval between blood measurements and carotid 
MRI scan was 7.9 years (standard deviation of 4.0 years).
Other risk factors in the Rotterdam Study
The information about other cardiovascular risk factors as relevant covariables was obtained by interview, 
physical examination, and blood sampling between the years 1998 and 2008 (11). Diabetes mellitus was 
defined as fasting blood glucose >6.9 mmol/L, nonfasting glucose >11.0 mmol/L, or use of glucose-
lowering medication. Systolic and diastolic blood pressure was measured using a random-zero 
sphygmomanometer on the right arm and two measurements were averaged for the analysis. Smoking 
status was assessed by interview and categorized into never, past, and current smoking. Body mass 
index (BMI) was calculated based on the weight in kilograms divided by height in meters squared. Waist 
circumference (WC) was measured at the midpoint between the lower rib and the iliac crest in all 
participants with standing position and gentle breathing. Total cholesterol and high-density lipoproteins 
(HDL) levels were measured using standard laboratory techniques. The information on the use of 
antihypertensive medication and lipid-lowering medication was obtained from pharmacy records (11). 
History of stroke or coronary heart disease (CHD) was self-reported at study entry and verified by clinical 
data from the medical records or the occurrence during study follow-up but before the time of carotid MRI 
scanning. 
Statistical analysis
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The distribution of continuous and categorical variables was described using means (standard deviations 
[SD]), medians (interquartile ranges [IQRs]), or percentages. We performed a natural logarithmic 
transformation to normalize the distributions of serum insulin and glucose. To investigate the association 
between fasting insulin and glucose levels with intraplaque hemorrhage (IPH), lipid core, and calcification, 
a three-step statistical analysis approach was used. First, we investigated the association between fasting 
insulin and glucose levels with the presence of each component in one or both carotid arteries using 
logistic regression models. In model 1, adjusted for sex, age, intima-media thickness and the time 
difference between insulin and glucose measurements and MRI scan. In model 2, additionally adjusted 
for smoking, serum high-density lipoprotein, serum total cholesterol, systolic and diastolic blood pressure, 
diabetes mellitus, body mass index, waist circumference, use of anti-diabetic medication, use of 
antihypertensive medication, and insulin or glucose levels, dependent on the determinant under 
investigation. In model 3, additionally adjusted for the use of lipid-lowering medication (13), vitamin K 
antagonists and antiplatelet agents (18). Second, we categorized serum insulin and glucose levels into 
tertiles and investigated the association of tertiles of insulin and glucose (lowest tertile was used as the 
reference category) with carotid plaque components using regression model 1. Third, we performed the 
following three sensitivity analyses.  In the first analysis, we investigated all the above-mentioned 
associations only in participants that had their MRI-scan and blood measurements within one year in 
order to assess the potential effect of the time delay between the measurements. In the second analysis, 
we reassessed all associations in participants that were free of diabetes mellitus at the time of the MRI. In 
the third analysis, we stratified all analyses for sex to investigate whether associations are different 
between males and females. Additionally, we investigated the association between serum insulin and 
glucose and intima-media thickness and association between HOMA index and carotid composition using 
regression models. All analyses were carried out using IBM SPSS Statistical package version 21 
(Chicago, IL, USA).
RESULTS
Table 1 shows the population characteristics at the MRI scan. The mean age of the population was 72.9 
years (9.1 years) and 46.0 percent were women. A total of 251 (14.4%) participants were diagnosed with 
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diabetes mellitus at baseline. The median (IQR) fasting insulin level was 74 (50–98) pmol/L and the 
median (IQR) fasting glucose level was 5.6 (5.2–6.0) mmol/L.
Associations between fasting insulin and glucose levels with the different plaque components are 
summarized in Table 2. We found that higher fasting insulin levels were associated with the presence of 
intraplaque hemorrhage (fully adjusted odds ratio (OR) per 1-SD increase in insulin level: 1.38 [95% 
confidence interval (CI): 1.09–1.74]) (Table 2, model 2). Further adjustment for antithrombotic treatment 
increased the estimate and empowered the association (OR per 1-SD increase: 1.42 [95% confidence 
interval (CI): 1.12–1.79]) (Table 2, model 3). No association was found with the presence of calcification 
or lipid core. Also, when assessing the glucose levels, we found no association between fasting glucose 
levels with any of the plaque components. Furthermore, no association was found between the HOMA 
index and carotid plaque components (Table 2). 
When investigating tertiles of insulin and glucose levels, we found that the high insulin level tertile was 
associated with a higher frequency of intraplaque hemorrhage (adjusted OR of highest versus lowest 
tertile: 1.32 [95% CI: 1.01–1.75]) and a lower frequency of lipid core (adjusted OR of highest versus 
lowest tertile: 0.69 [95% CI: 0.54–0.88]) compared to the low tertile (Figure 2). Again, for glucose, we did 
not find any association with the various plaque components (Figure 3).
When restricting analyses only to participants who had both measurements (insulin and glucose 
measurements and MRI scan) within 6-months (n=122) or less and within one year (n=212), the results 
were in a similar trend (Table S1 and Table S2). Similarly, the results did not change when we excluded 
participants with a diagnosis of diabetes mellitus at the time of MRI (n=1489) (Table S3). Furthermore, 
after stratifying the analyses by sex similar effect estimates, between males and females, for the relation 
of serum insulin levels with IPH and lipid core. Whereas no association was observed for calcification in 
both sexes. Also, when assessing the relationship between glucose and plaque components no 
association was observed in either sex (Table S4). Moreover, when assessing the relationship between 
serum insulin or glucose and carotid intima-media thickness no association was found (Table S5). No 
further stratified analyses were performed for the HOMA index. 
DISCUSSION
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In this large population-based study of subjects with subclinical carotid atherosclerosis, we observed that 
higher fasting serum insulin levels were associated with the presence of intraplaque hemorrhage within 
the carotid atherosclerotic plaque. We did not find an association between fasting glucose levels and any 
of the carotid plaque components. 
Until now, most of the evidence linking insulin and glucose to atherosclerosis comes from studies in which 
atherosclerotic cardiovascular clinical endpoints, such as ischemic heart disease or ischemic stroke, were 
investigated (19-21). Hyperinsulinemia was found to increase the risk of ischemic heart disease among 
4637 middle-aged men from the Quebec Cardiovascular Study (19), and the risk of acute coronary and 
cerebrovascular events in 1521 men enrolled in Kuopio Ischemic Heart Disease Risk Factor Study (20). 
Our results extend on these findings by showing that preclinical changes in serum insulin levels relate to 
a more vulnerable composition of the carotid atherosclerotic plaque. More specifically, we demonstrated 
that high serum insulin levels, especially relate to the presence of intraplaque hemorrhage, the plaque 
component which is regarded as the most vulnerable (22). Similarly, insulin was found to increase 
intraretinal hemorrhage and extraretinal neovascularization in rats (23). Previous animal studies 
described insulin to play a pleiotropic effect on the vascular system, through vascular endothelial growth 
factor (VEGF), which plays a pivotal role in angiogenesis (23, 24). High levels of insulin increase the 
levels of VEGF, which in turn induce abnormal neovascularization that is prone to leakage and 
hemorrhage (23).  
In contrast to high or low serum insulin levels, it may be speculated that physiological concentration levels 
(median levels 66–85 pmol/L) potentially behave protectively against atherosclerosis. Observations in our 
study showed that medium levels of serum insulin were not associated with any vulnerable plaque 
component, but were associated with a lower presence of calcification, which may support the hypothesis 
that medium levels of serum insulin have the protective effect (Figure 2). In the same line, a recent animal 
study examined the role of insulin in atherosclerotic plaque reported the protective effect of insulin on 
atherosclerosis (22). In this study, the insulin effect was tested on atherosclerosis in a mouse model, and 
insulin was found to decrease the plaque burden and increased plaque stability via nitric oxide synthase 
(NOS) mechanisms (22). Furthermore, it was found that insulin reduced macrophage accumulation, 
plaque necrosis, and increased collagen and smooth muscle cell accumulation (22). However, it seems 
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that only disrupted levels of serum insulin, low and high insulin levels, link serum insulin with 
atherosclerosis. Previously, animal studies demonstrated also that impaired insulin signaling by genetic 
modification accelerated atherosclerosis (25-27).
Surprisingly, we found no effects of serum glucose levels in carotid plaque composition. In the context of 
glucose, our findings are in contrast with studies that link glucose levels below 7.0 mmol/L with an 
increased risk of vascular disease (28). However, a recent meta-analysis of 102 prospective studies that 
investigated the relationship between fasting glucose levels and risk of vascular diseases concluded that 
glucose concentrations were non-linear and modestly associated with the risk of vascular diseases 
among individuals without diabetes (21), meaning that glucose levels below and higher than 7.0 mmol/L 
were associated with increased risk for coronary heart disease and ischemic stroke (21).
In terms of clinical practice, our findings may have clinical implications given that these suggest that 
fasting serum insulin conveys information on the atherosclerotic plaque composition that may ultimately 
be used for risk stratification of patients in daily practice. 
The major strength of our study includes the largest population-based sample of individuals with 
subclinical carotid atherosclerosis and the MRI-based assessment carotid plaque composition. Given the 
accurate diabetes assessments within the Rotterdam Study, we were able to address for the first time the 
association between subclinical variations of insulin and glucose levels with atherosclerotic disease. 
Nevertheless, our study should be interpreted in the context of some limitations. First, the cross-sectional 
study design limits us to draw causal inferences between fasting insulin and atherosclerotic plaque 
components. Second, in a substantial part of our study population, the time interval between insulin and 
glucose measurements and MRI scanning was more than 2 years. However, limiting our analyses to the 
subgroup of participants with available measurements of MRI and serum insulin levels in the same year 
did show different associations.
CONCLUSION
In conclusion, serum insulin levels are associated with the presence of vulnerable components of carotid 
plaque, specifically with intraplaque hemorrhage, suggesting that serum insulin may play a role in the 
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vulnerability of carotid atherosclerotic plaque. Further studies are required to confirm our findings in a 
longitudinal design.
Funding/Support: 
The Rotterdam Study is supported by the Erasmus MC and Erasmus University Rotterdam; the 
Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health 
Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the 
Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture and Science, the Ministry of 
Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. MK is 
supported by the VENI grant (91616079) from ZonMw.
None of the funders had any role in the design and conduct of the study; collection, management, 
analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Role of the Funder/Sponsor: 
The funding sources had no role in the design and conduct of the study; collection, management, 
analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision 
to submit the manuscript for publication.
Acknowledgments
The dedication, commitment, and contribution of the inhabitants, general practitioners, and pharmacists of 
the Ommoord district to the Rotterdam Study are gratefully acknowledged.
Conflict of Interest Disclosures: 
The authors report no potential conflicts of interest.
Authors' contributions:
Study concept and design: BM, DB, OHF. Acquisition, analysis or interpretation of data: BM, DB, OHF. 
Drafting of the manuscript: BM. Critical revision of the manuscript for important intellectual content: BM, 
DB, MK, AVL, JAS, OHF*, MWV*. Statistical analysis: BM. Administrative, technical, or material support: 
BM, DB, OHF. All authors read and approved the final manuscript.
Page 10 of 26Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
11
11
* denotes the equal contribution
REFERENCES:
1. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review 
of the evidence. Journal of the American College of Cardiology. 2010;55(13):1310-7.
2. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of 
cardiovascular disease: a meta-analysis. Circulation. 1998;97(10):996-1001.
3. Sekine O, Nishio Y, Egawa K, Nakamura T, Maegawa H, Kashiwagi A. Insulin activates 
CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 
3-kinase pathway in vascular smooth muscle cells. The Journal of biological chemistry. 
2002;277(39):36631-9.
4. Wang CC, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and 
migration via distinct signaling pathways. Diabetes. 2003;52(10):2562-9.
5. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial 
dysfunction. Endocrinology and metabolism clinics of North America. 2008;37(3):685-711, ix-x.
6. Saam T, Hetterich H, Hoffmann V, Yuan C, Dichgans M, Poppert H, Koeppel T, Hoffmann U, 
Reiser MF, Bamberg F. Meta-analysis and systematic review of the predictive value of carotid plaque 
hemorrhage on cerebrovascular events by magnetic resonance imaging. Journal of the American College 
of Cardiology. 2013;62(12):1081-91.
7. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, Dunning A, Mushlin AI, 
Sanelli PC. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke. 
2013;44(11):3071-7.
8. van den Bouwhuijsen QJA, Vernooij MW, Verhaaren BFJ, Vrooman HA, Niessen WJ, Krestin GP, 
Ikram MA, Franco OH, van der Lugt A. Carotid Plaque Morphology and Ischemic Vascular Brain Disease 
on MRI. American Journal of Neuroradiology. 2017;38(9):1776-82.
9. Selwaness M, Bos D, van den Bouwhuijsen Q, Portegies ML, Ikram MA, Hofman A, Franco OH, 
van der Lugt A, Wentzel JJ, Vernooij MW. Carotid Atherosclerotic Plaque Characteristics on Magnetic 
Resonance Imaging Relate With History of Stroke and Coronary Heart Disease. Stroke. 2016;47(6):1542-
7.
Page 11 of 26 Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
12
12
10. Singh N, Moody AR, Roifman I, Bluemke DA, Zavodni AEH. Advanced MRI for carotid plaque 
imaging. The International Journal of Cardiovascular Imaging. 2016;32:83-9.
11. Ikram MA, Brusselle GGO, Murad SD, van Duijn CM, Franco OH, Goedegebure A, Klaver CCW, 
Nijsten TEC, Peeters RP, Stricker BH, et al. The Rotterdam Study: 2018 update on objectives, design 
and main results. Eur J Epidemiol. 2017;32(9):807-50.
12. van den Bouwhuijsen QJ, Vernooij MW, Hofman A, Krestin GP, van der Lugt A, Witteman JC. 
Determinants of magnetic resonance imaging detected carotid plaque components: the Rotterdam Study. 
Eur Heart J. 2012;33(2):221-9.
13. Mujaj B, Bos D, Selwaness M, Leening MJG, Kavousi M, Wentzel JJ, van der Lugt A, Hofman A, 
Stricker BH, Vernooij MW, et al. Statin use is associated with carotid plaque composition: The Rotterdam 
Study. International journal of cardiology. 2018;260:213-8.
14. Mujaj B, Lorza AM, van Engelen A, de Bruijne M, Franco OH, van der Lugt A, Vernooij MW, Bos 
D. Comparison of CT and CMR for detection and quantification of carotid artery calcification: the 
Rotterdam Study. Journal of cardiovascular magnetic resonance : official journal of the Society for 
Cardiovascular Magnetic Resonance. 2017;19(1):28.
15. Neeley WE. Simple automated determination of serum or plasma glucose by a hexokinase-
glucose-6 -phosphate dehydrogenase method. Clinical chemistry. 1972;18(6):509-15.
16. Wieberdink RG, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB, Arfan Ikram M. Insulin 
Resistance and the Risk of Stroke and Stroke Subtypes in the Nondiabetic Elderly. American Journal of 
Epidemiology. 2012;176(8):699-707.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis 
model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin 
concentrations in man. Diabetologia. 1985;28(7):412-9.
18. Mujaj B, Bos D, Muka T, Lugt AV, Ikram MA, Vernooij MW, Stricker BH, Franco OH. 
Antithrombotic treatment is associated with intraplaque haemorrhage in the atherosclerotic carotid artery: 
a cross-sectional analysis of The Rotterdam Study. Eur Heart J. 2018;39(36):3369-76.
Page 12 of 26Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
13
13
19. Després J-P, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. 
Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease. New England Journal of 
Medicine. 1996;334(15):952-8.
20. Lakka H, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of 
cardiovascular death and acute coronary and cerebrovascular events in men: The kuopio ischaemic heart 
disease risk factor study. Archives of Internal Medicine. 2000;160(8):1160-8.
21. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, 
Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular 
disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England). 
2010;375(9733):2215-22.
22. Mori Y, Chiang S, Bendeck MP, Giacca A. Insulin decreases atherosclerotic plaque burden and 
increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice. Am J Physiol Endocrinol 
Metab. 2016;311(2):E335-45.
23. Yoo M-H, Yoon YH, Chung H, Cho KS, Koh J-Y. Insulin Increases Retinal Hemorrhage in Mild 
Oxygen-Induced Retinopathy in the Rat: Inhibition by Riluzole. Investigative Ophthalmology & Visual 
Science. 2007;48(12):5671-6.
24. Escudero CA, Herlitz K, Troncoso F, Guevara K, Acurio J, Aguayo C, Godoy AS, González M. 
Pro-angiogenic Role of Insulin: From Physiology to Pathology. Front Physiol. 2017;8:204-.
25. Baumgartl J, Baudler S, Scherner M, Babaev V, Makowski L, Suttles J, McDuffie M, Tobe K, 
Kadowaki T, Fazio S, et al. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-
deficient mice against atherosclerosis. Cell Metab. 2006;3(4):247-56.
26. Clough MH, Schneider DJ, Sobel BE, White MF, Wadsworth MP, Taatjes DJ. Attenuation of 
accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 
and apolipoprotein E. The journal of histochemistry and cytochemistry : official journal of the 
Histochemistry Society. 2005;53(5):603-10.
27. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Y, Prendergast J, Miao RQ, 
Birnbaum MJ, Sessa WC. Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery 
disease. Cell Metab. 2007;6(6):446-57.
Page 13 of 26 Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
14
14
28. Al-Mashhadi RH, Bjorklund MM, Mortensen MB, Christoffersen C, Larsen T, Falk E, Bentzon JF. 
Diabetes with poor glycaemic control does not promote atherosclerosis in genetically modified 
hypercholesterolaemic minipigs. Diabetologia. 2015;58(8):1926-36.
Page 14 of 26Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
15
Table 1  Baseline characteristics of the study population (n=1740)
Page 15 of 26 Accepted Manuscript published as EJE-19-0620.R3. Accepted for publication: 20-Jan-2020
Copyright © 2019 European Society of Endocrinology Downloaded from Bioscientifica.com at 01/27/2020 12:46:48PM
via Universitatsbibliothek Bern
16
Table 2  Association serum insulin, glucose and HOMA index with carotid artery plaque composition 
(n=1740)
Figure 3  Association of serum glucose levels (tertiles) with plaque composition in the carotid artery. 
Values on the x-axis represent the odds ratios and 95% confidence interval. The values are adjusted 
for sex, age, and intima-media thickness. Statistics was performed using logistic regression using total 
sample of subjects n=1740. P-trend over categories of glucose for intraplaque hemorrhage was 0.87, 
for lipid core was 0.33 and for calcification was 0.81.
Figure 2  Association of serum insulin levels (tertiles) with plaque composition in the carotid artery. 
Values on the x-axis represent the odds ratios and 95% confidence interval. The values are adjusted 
for sex, age, and intima-media thickness. Statistics was performed using logistic regression using total 
sample of subjects n=1740. P-trend over categories of insulin for intraplaque hemorrhage was 0.04, 
for lipid core was 0.003 and for calcification was 0.32. 
Figure 1  Flow chart of the participants included in the analysis. 
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Table 1  Baseline characteristics of the study population (n=1740). Values are presented as mean ± S.D. and median (interquartile ranges) for 
continuous variables and percentages for dichotomous or categorical variables. P-values were derived by Fisher’s exact test or analysis of variance 
(ANOVA). 
Characteristics Insulin P-value Total
≤57 58–89 >90
Number in category 587 615 538 1740
Age, years (SD) 74.0±8.8 73.4±9.1 71.1±9.4 <0.001 72.9±9.1
Women, % 48.9 47.2 41.4 0.03 46.0
Smoking, current % 43.3 41.1 42.9 0.41 42.4
Diabetes mellitus, % 8.2 11.4 24.7 <0.001 14.4
Fasting glucose, mmol/L (SD) 5.3 (5.0–5.7) 5.6 (5.2–5.9) 5.9 (5.4–6.5) <0.001 5.6 (5.2–6.0)
Fasting insulin, pmol/L 44 (35–51) 75 (66–85) 121 (100–165) <0.001 74 (50–98)
Homa index 2.3 (2.1–2.5) 2.9 (2.7–3.1) 3.4 (3.2–3.8) <0.001 2.9 (2.5–3.2) 
Systolic blood pressure, mm/Hg (SD) 144±20 147±20 144±20 0.02 145±20
Diastolic blood pressure, mm/Hg (SD) 79±10 81±10 81±11 0.001 80±10
BMI, kg/m2 (SD) 25.7±3.0 27.1±3.1 29.2±3.7 <0.001 27±3.5
Waist circumference, cm 89.7±9.9 93.8±10.0 99.9±11.0 <0.001 94.3±11.1
Total cholesterol, mmol/L (SD) 5.6±1.0 5.7±1.0 5.5±1.0 0.004 5.6±1.0
HDL cholesterol, mmol/L (SD) 1.5±0.3 1.4±0.3 1.2±0.3 <0.001 1.4±0.3
Antihypertensive medication, % 32.0 36.6 50.4 <0.001 39.3
Antidiabetic medication, % 6.3 8.3 19.0 <0.001 10.9
Statin use, % 25.6 28.6 33.3 0.02 29.0
Vitamin K antagonists, % 5.8 5.7 5.2 0.90 5.6
Antiplatelet agents; % 27.6 26.5 28.4 0.76 27.5
Intima-media thickness, mm 3.2±0.6 3.2±0.6 3.2±0.7 0.77 3.2±0.6
Degree of stenosis, (%) 12.3 (0.0–25.9) 14.5 (0.0–26.4) 15.2 (0.0–28.0) 0.16 14.5 (0.0–26.8)
History of stroke, % 4.6 7.2 6.5 0.02 6.3
History of coronary heart disease, % 12.8 10.1 11.5 0.01 11.4
Presence of calcification, % 85.7 80.2 81.0 0.02 82.3
Presence of lipid core, % 47.2 45.5 38.8 0.01 44.0
Presence of intraplaque hemorrhage, % 32.5 35.9 35.5 0.41 34.7
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Table 2  Association serum insulin, glucose and HOMA index with carotid artery plaque composition 
(n=1740) and glucose (per S.D. increment) with intraplaque hemorrhage (IPH), lipid core and calcification. 
Data are presented as OR (95% CI).
IPH Lipid core Calcification
Insulin
Model 1 1.27 (1.05–1.55) 0.76 (0.63–0.90) 0.93 (0.74–1.16)
Model 2* 1.38 (1.09–1.74) 0.89 (0.72–1.10) 1.06 (0.80–1.39)
Model 3 1.42 (1.12–1.79) 0.90 (0.73–1.11) 1.05 (0.79–1.39)
Glucose
Model 1 1.04 (0.55–1.96) 0.51 (0.29–0.91) 1.19 (0.58–2.47)
Model 2† 0.47 (0.18–1.19) 1.09 (0.48–2.46) 0.90 (0.31–2.58)
Model 3 0.45 (0.18–1.16) 1.10 (0.49–2.49) 0.90 (0.31–2.57)
HOMA index
Model 1 1.65 (1.01–2.71) 0.49 (0.32–0.77) 0.80 (0.45–1.44)
Model 2*† 0.37 (0.03–4.51) 1.33 (0.13–13.8) 0.05 (0.01–1.85)
Model 3 0.39 (0.03–4.74) 1.36 (0.13–14.1) 0.05 (0.01–2.01)
Model 1 = adjusted for sex, age, intima-media thickness and the time difference between insulin and glucose 
measurements and MRI scan. Model 2 = model 1 + smoking, high-density lipoprotein, total cholesterol, 
systolic and diastolic blood pressure, diabetes mellitus, body mass index, waist circumference, use of anti-
diabetic medication, use of antihypertensive medication and *glucose or †insulin levels. Model 3 = model 2 
+ use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.
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Table S1   Association serum insulin and glucose levels with carotid artery plaque composition in the ≤ 6-
months difference between MRI and insulin measurements (n=122)
Insulin IPHOR (95%CI)
Lipid core
OR (95%CI)
Calcification
OR (95%CI)
Model 1 1.23 (0.65–2.32) 0.56 (0.29–1.11) 0.73 (0.33–1.59)
Model 2* 2.23 (0.88–5.66) 0.70 (0.27–1.77) 0.68 (0.17–2.64)
Model 3 2.41 (0.90–6.44) 0.64 (0.24–1.70) 0.44 (0.09–2.16)
Glucose
Model 1 0.83 (0.12–5.82) 0.35 (0.05–2.46) 0.33 (0.02–4.03)
Model 2† 0.03 (0.01–1.13) 0.21 (0.07–5.80) 0.00 (0.00–0.70)
Model 3 0.04 (0.01–1.64) 0.24 (0.00–7.29) 0.00 (0.00–0.26)
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between serum insulin 
and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core and calcification. Model 1 = 
adjusted for sex, age, intima-media thickness and the time difference between insulin and glucose 
measurements and MRI scan. Model 2 = model 1 + smoking, high-density lipoprotein, total cholesterol, 
systolic and diastolic blood pressure, diabetes mellitus, body mass index, waist circumference, use of anti-
diabetic medication, use of antihypertensive medication and *glucose or †insulin levels. Model 3 = model 2 
+ use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.
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Table S2   Association serum insulin and glucose levels with carotid artery plaque composition in the ≤ 1-
year difference between MRI and insulin measurements (n=212)
Insulin IPHOR (95%CI)
Lipid core
OR (95%CI)
Calcification
OR (95%CI)
Model 1 1.50 (0.85–2.64) 0.41 (0.23–0.74) 0.98 (0.55–1.75)
Model 2* 2.02 (0.97–4.19) 0.41 (0.20–0.84) 0.96 (0.45–2.06)
Model 3 2.41 (1.11–5.21) 0.40 (0.20–0.83) 0.97 (0.45–2.11)
Glucose
Model 1 1.03 (0.20–5.44) 0.20 (0.36–1.08) 1.38 (0.25–7.58)
Model 2† 0.22 (0.20–2.84) 0.49 (0.05–4.88) 0.22 (0.02–2.64)
Model 3 0.16 (0.01–2.43) 0.52 (0.05–5.20) 0.21 (0.02–2.66)
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between serum insulin 
and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core and calcification. Model 1 = 
adjusted for sex, age, intima-media thickness and the time difference between insulin and glucose 
measurements and MRI scan. Model 2 = model 1 + smoking, high-density lipoprotein, total cholesterol, 
systolic and diastolic blood pressure, diabetes mellitus, body mass index, waist circumference, use of anti-
diabetic medication, use of antihypertensive medication and *glucose or †insulin levels. Model 3 = model 2 
+ use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.
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Table S3 Association serum insulin and glucose levels with carotid artery plaque composition in individuals 
free of diabetes mellitus (n=1489)
Insulin IPHOR (95%CI)
Lipid core
OR (95%CI)
Calcification
OR (95%CI)
Model 1 1.32 (1.05–1.66) 0.78 (0.64–0.96) 0.99 (0.76–1.29)
Model 2* 1.43 (1.09–1.87) 0.87 (0.68–1.11) 1.08 (0.78–1.49)
Model 3 1.46 (1.12–1.92) 0.88 (0.69–1.12) 1.06 (0.77–1.47)
Glucose
Model 1 0.71 (0.21–2.43) 0.90 (0.30–2.67) 1.31 (0.32–5.38)
Model 2† 0.40 (0.10–1.55) 1.85 (0.56–6.12) 0.91 (0.19–4.27)
Model 3 0.41 (0.11–1.60) 1.85 (0.56–6.18) 0.93 (0.20–4.38)
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between serum insulin 
and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core and calcification. Model 1 = 
adjusted for sex, age, intima-media thickness and the time difference between insulin and glucose 
measurements and MRI scan. Model 2 = model 1 + smoking, high-density lipoprotein, total cholesterol, 
systolic and diastolic blood pressure, body mass index, waist circumference, use of antihypertensive 
medication and *glucose or †insulin levels. Model 3 = model 2 + use of lipid-lowering medication, vitamin K 
antagonists and antiplatelet agents.
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Table S4 Association serum insulin and glucose levels with carotid artery plaque composition stratified by 
sex
Females (n=800)
IPH
OR (95%CI)
Lipid core
OR (95%CI)
Calcification
OR (95%CI)
Insulin
Model 1 1.16 (0.87–1.57) 0.72 (0.55–0.94) 0.95 (0.68–1.32)
Model 2 1.25 (0.87–1.79) 0.82 (0.60–1.13) 1.04 (0.70–1.56)
Model 3* 1.26 (0.88–1.81) 0.81 (0.58–1.12) 1.02 (0.67–1.54)
Glucose Model 1 1.80 (0.61–5.32) 0.64 (0.24–1.72) 1.15 (0.33–4.08)
Model 2 1.13 (0.24–5.30) 3.84 (0.92–16.13) 2.27 (0.38–13.69)
Model 3† 1.11 (0.23–5.28) 4.19 (0.98–17.88) 2.42 (0.39–15.17)
Males (n=940) IPH
OR (95%CI)
Lipid core
OR (95%CI)
Calcification
OR (95%CI)
Insulin Model 1 1.35 (1.04–1.74) 0.90 (0.68–1.17) 0.92 (0.67–1.24)
Model 2 1.52 (1.11–2.06) 0.93 (0.70–1.22) 1.08 (0.75–1.58)
Model 3* 1.57 (1.15–2.14) 0.93 (0.71–1.24) 1.07 (0.74–1.56)
Glucose Model 1 0.74 (0.33–1.67) 0.46 (0.22–0.95) 1.18 (0.48–2.85)
Model 2 0.31 (0.10–0.98) 0.64 (0.24–1.71) 0.85 (0.25–2.88)
Model 3† 0.30 (0.09–0.96) 0.65 (0.24–1.72) 0.84 (0.25–3.14)
Odds ratio (OR), given with a 95% confidence interval (CI), express the relationship between serum insulin 
and glucose (per SD increment) with intraplaque hemorrhage (IPH), lipid core and calcification. Model 1 = 
adjusted for sex, age, intima-media thickness and the time difference between insulin and glucose 
measurements and MRI scan. Model 2 = model 1 + smoking, high-density lipoprotein, total cholesterol, 
systolic and diastolic blood pressure, diabetes mellitus, body mass index, waist circumference, use of anti-
diabetic medication, use of antihypertensive medication and *glucose or †insulin levels. Model 3 = model 2 
+ use of lipid-lowering medication, vitamin K antagonists and antiplatelet agents.
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Table S5 Association serum insulin and glucose levels with intima-media thickness (n=1740)
Insulin Beta 95% CI p-value
Model 1  0.009 -0.048–0.066 0.75
Model 2 -0.009 -0.077–0.059 0.80
Model 3*  0.001 -0.067–0.069 0.97
Glucose
Model 1  0.034 -0.154–0.222 0.72
Model 2  0.015 -0.248–0.277 0.91
Model 3†  0.012 -0.249–0.274 0.93
Effect size, given with a 95% confidence interval (CI), express the relationship between serum insulin and 
glucose (per SD increment) intima-media thickness. Model 1 = adjusted for sex, age, intima-media thickness 
and time difference between insulin and glucose measurements and MRI scan. Model 2 = model 1 + 
smoking, high-density lipoprotein, total cholesterol, systolic and diastolic blood pressure, diabetes mellitus, 
body mass index, waist circumference, use of anti-diabetic medication, use of antihypertensive medication 
and *glucose or †insulin levels. Model 3 = model 2 + use of lipid-lowering medication, vitamin K antagonists 
and antiplatelet agents. 
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